If a medication is available in the US but not in your country, read When conventional access fails.
Specialty drug access in the UAE: the named-patient pathway
From first request to drug delivery, a transparent walkthrough of every step.
Last reviewed 2026-05-01 by Reserve Meds clinical & regulatory team. UAE patients have one of the most mature named-patient frameworks in the GCC. Here is how it actually works.
Why UAE patients face an access gap in the first place
The UAE pharmaceutical market is well-organized and well-regulated. The Ministry of Health and Prevention (MoHAP) maintains a federal drug registration list. Dubai Health Authority (DHA) regulates the Dubai emirate; Department of Health Abu Dhabi (DoH) regulates Abu Dhabi emirate. Each handles registration submissions for new medicines.
Despite this, UAE patients regularly face three gaps:
- Registered but not stocked. A drug is on the MoHAP list but a particular hospital pharmacy does not have it on hand. The patient's care team has confirmed the drug is appropriate; supply timing is the bottleneck.
- Registered for a different indication. A drug is registered for, say, rheumatoid arthritis but the physician is prescribing it for inflammatory bowel disease where it is FDA-approved but not locally registered for that use.
- Not registered in the UAE at all. A drug is FDA-approved in the United States but the manufacturer has not pursued UAE registration, often because the patient population is small (rare diseases, certain orphan oncology drugs).
Each of these gaps has the same regulatory remedy: the named-patient import pathway.
The MoHAP named-patient pathway
The MoHAP named-patient framework allows a UAE-licensed physician to request import of a specific medicine for a specific patient when the medicine is approved by a recognised reference authority (typically the US FDA, EMA, MHRA, or Health Canada) and a clinically equivalent locally registered alternative is not suitable. The framework is mature: it has supported access to oncology, rare disease, immunology, and pediatric medicines for many years.
The application is filed by either the treating physician directly or, more commonly, by the dispensing hospital's import pharmacy on the physician's behalf. It includes:
- A clinical justification letter (diagnosis, severity, prior therapies, why this specific drug)
- The treating physician's UAE medical license verification
- A patient identifier (anonymized reference is preferred)
- The product details: brand name, generic name, manufacturer, strength, quantity
- The destination dispensing facility and its license
- A chain-of-custody plan describing how the medicine will move from the US manufacturer to the dispensing pharmacy
Approval timelines for routine cases are typically 5-15 business days. Complex cases (rare drug, novel mechanism, off-label use) can extend to 4-6 weeks. Urgent oncology cases can sometimes receive expedited review.
Dubai-specific: the DHA layer
If the dispensing facility is in Dubai, DHA's Pharmaceutical Affairs department issues a complementary approval that runs in parallel with MoHAP. DHA's process is generally fast and well-documented; the Dubai Health Authority maintains an explicit named-patient pathway that the major Dubai oncology centers use routinely. American Hospital Dubai, Mediclinic City Hospital, and King's College Hospital London Dubai are among the institutions that handle named-patient import as a standard workflow.
Abu Dhabi: the DoH layer
If the dispensing facility is in Abu Dhabi, DoH (Department of Health Abu Dhabi) handles the emirate-level approval. SEHA, the public health system operator, has internal processes for named-patient procurement at its tertiary centers. Cleveland Clinic Abu Dhabi, NMC Royal, and Sheikh Khalifa Medical City have established workflows for import.
Real costs: what UAE patients actually pay
Costs vary widely by drug, but for context, a 30-day supply of a major specialty oral oncology drug (for example, an ALK inhibitor or BTK inhibitor) typically falls in a USD 6,000-12,000 monthly range for the drug itself, plus international logistics (USD 400-1,500 depending on cold chain), plus regulatory documentation handling fees, plus our concierge fee.
For a CAR-T or gene therapy with a list price of USD 400,000-2,000,000, the cost structure changes: the drug dominates everything else, and Reserve Meds' role shifts from cost management to logistical and regulatory orchestration.
The waitlist form generates an indicative range first, then a transparent firm quote with each line item separated. Nothing is bundled or hidden.
The patient experience: what your family actually does
From the family side, the process looks like this:
- Your physician decides this drug is the right next step. That is a clinical decision and stays with them.
- Your physician (or the hospital's pharmacy team) reaches out to Reserve Meds, or the patient submits the waitlist request and we connect with the physician.
- We confirm eligibility within 24-48 hours and send a documentation kit to your physician.
- Your physician fills out the named-patient application and submits it to MoHAP / DHA / DoH.
- While the application processes (5-15 business days for most cases), Reserve Meds aligns the US-side sourcing and shipment plan.
- Approval comes through. We ship cold-chain (or ambient, depending on the drug). Your hospital pharmacy receives the medicine.
- Your physician initiates therapy.
You, the patient and family, see: an indicative quote, a firm quote, a wire confirmation, a tracking link, and a delivery confirmation. Your physician handles the regulatory side; we handle the logistical side; you focus on the clinical care.
Common UAE-specific questions
Will Daman cover this?
Daman, Thiqa, and most UAE private health insurance plans handle named-patient imports on a case-by-case basis. Some plans reimburse fully when the drug is on their formulary even if not stocked locally; others reimburse a portion; some require pre-authorization. Reserve Meds provides documentation that allows your insurer to assess the case; we do not process insurance claims directly. Cash-pay is the default posture and many UAE patients reimburse themselves later if their plan covers.
What if the drug is a controlled substance?
Reserve Meds does not handle controlled substances (DEA Schedule I-V). UAE controlled-substance import requires Federal Narcotics Department coordination that runs separately from named-patient approval; we refer those cases to specialists.
Can I receive the drug at home or do I need a hospital?
The dispensing facility must be UAE-licensed. For oral medicines, a hospital outpatient pharmacy or a specialized import pharmacy can dispense. For infusion products, the medicine ships to the infusion center where you will receive it. Direct-to-home delivery without a licensed dispensing facility in the chain is not the model.
What about pediatric patients?
The framework applies the same way for pediatric patients. The clinical justification letter typically includes weight-adjusted dosing and pediatric-specific monitoring requirements. Dubai's pediatric oncology centers and Sheikh Khalifa Medical City's pediatric service handle named-patient imports routinely.
Can my physician in another GCC country prescribe and have it shipped to me in the UAE?
The named-patient pathway is patient-resident-based; a UAE patient needs a UAE-licensed prescribing physician for the application. We can help your home physician coordinate with a UAE-licensed colleague if that is the right structure.
Comparison with adjacent GCC frameworks
UAE's MoHAP framework is generally faster and more documented than its peers. Saudi Arabia's SFDA framework is comparably mature but has stricter pharmacovigilance reporting requirements post-import. Qatar's MoPH framework handles named-patient cases but with a smaller specialty pharmacy infrastructure than UAE. Kuwait's MoH framework is established but slower (typically 3-6 weeks). Bahrain's NHRA framework is functional for routine cases but is best for less complex imports. Oman's framework is the least developed of the GCC; cases there often route through UAE-based specialty centers.
Where Reserve Meds fits
Reserve Meds is a US-based concierge coordinator. We do not replace your physician, do not replace MoHAP, do not replace your dispensing pharmacy. What we do is orchestrate the US-side sourcing, the regulatory documentation kit your physician needs, the international logistics, and a single named coordinator throughout your case.
For specialty oncology, rare disease, immunology, neurology, and other specialty therapies, this orchestration is the difference between a 6-week ad-hoc process for your hospital pharmacy and a 7-15-business-day predictable cycle.
This guide is informational, not medical or legal advice. The named-patient framework requires a licensed UAE physician's clinical judgment; Reserve Meds is the coordinator, not the prescriber.
Drug-access guides for UAE
Each guide below is a named-patient access pathway for that specific drug in UAE, with real timelines, costs, and the documentation your physician needs. These are coordinated by Reserve Meds for cross-border procurement.